XML 85 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE - Narrative (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 22, 2024
USD ($)
Dec. 27, 2023
USD ($)
Dec. 12, 2023
USD ($)
Aug. 14, 2023
USD ($)
intangibleAsset
Jul. 21, 2022
USD ($)
intangibleAsset
Apr. 30, 2021
USD ($)
intangibleAsset
Jun. 30, 2023
USD ($)
intangibleAsset
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Nov. 19, 2021
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Money Market Fund               $ 191,841,000      
Payments on contingent consideration               12,500,000 $ 0 $ 0  
Intangible asset impairment charge               0 112,000 2,374,000  
Consideration               9,643,000 7,579,000 21,081,000  
Intangible assets acquired               9,600,000      
Finite-lived intangible gross carrying amount               497,332,000 480,915,000    
Research and development               34,286,000 22,318,000 $ 11,369,000  
Inventories               111,196,000 105,355,000    
Raw materials               62,237,000 67,726,000    
Finished goods               36,198,000 28,020,000    
Sandoz                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Intangible asset impairment charge               0 0    
Amortization period           7 years          
Total asset purchase           $ 20,700,000          
Finite-lived intangible gross carrying amount           11,400,000          
Transaction costs           400,000          
Inventories           9,700,000          
Raw materials           600,000          
Sample inventory           1,000,000          
Finished goods           $ 8,100,000          
Measurement Input, Discount Rate | Sandoz                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Intangible asset measurement input           10          
Oakrum Pharma                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Intangible asset impairment charge               0      
Amortization period         7 years            
Slayback Pharma Limited Liability, Company Patents and Pending Patents                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Intangible asset impairment charge               0      
Akorn Holding Company, Pipeline Product                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Intangible asset impairment charge               0      
Acquired ANDA intangible assets                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Intangible asset impairment charge               0 100,000    
Finite-lived intangible gross carrying amount               209,780,000 195,862,000    
Acquired ANDA intangible assets | Oakrum Pharma                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Intangible assets acquired         $ 7,200,000            
Amortization period         7 years            
Total asset purchase         $ 8,000,000            
Finite-lived intangible gross carrying amount         7,200,000            
Research and development         1,200,000            
Contingent liability not recognized, asset acquisition         $ 200,000            
Acquired ANDA intangible assets | Oakrum Pharma | Measurement Input, Discount Rate                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Intangible asset measurement input         13            
Acquired ANDA intangible assets | Slayback Pharma Limited Liability, Company Patents and Pending Patents                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Consideration       $ 3,000,000.0              
Intangible assets acquired       $ 2,800,000              
Amortization period       7 years              
Number of intangible assets acquired | intangibleAsset       1 4   2        
Acquired ANDA intangible assets | Akorn Holding Company, Pipeline Product                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Intangible assets acquired             $ 4,300,000        
Amortization period             7 years        
Total asset purchase             $ 4,800,000        
Product Intellectual Property | Alvogen Inc                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Consideration   $ 2,000,000                  
Intangible assets acquired   $ 2,000,000                  
Amortization period   7 years                  
Acquired pipeline product | Slayback Pharma Limited Liability, Company Patents and Pending Patents                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Number of intangible assets acquired | intangibleAsset             1        
Acquired commercial product | Slayback Pharma Limited Liability, Company Patents and Pending Patents                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Number of intangible assets acquired | intangibleAsset         1            
Acquired approved product | Slayback Pharma Limited Liability, Company Patents and Pending Patents                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Number of intangible assets acquired | intangibleAsset         1            
Acquired filed products | Slayback Pharma Limited Liability, Company Patents and Pending Patents                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Number of intangible assets acquired | intangibleAsset         2            
Acquired NDA intangible assets | Slayback Pharma Limited Liability, Company Patents and Pending Patents                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Number of intangible assets acquired | intangibleAsset           3          
Novitium                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Additional contingent consideration               $ 46,500,000      
Contingent consideration period               24 months      
Contingent consideration               $ 23,984,000 35,058,000   $ 30,800,000
Payments on contingent consideration     $ 12,500,000                
Novitium | Subsequent Event                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Payments on contingent consideration $ 12,500,000                    
Interest rate swap                      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]                      
Interest rate swaps, liability               $ 6,200,000 $ 8,800,000